Innovators in nutrition, health and beauty. Read more about our new company at dsm-firmenich.com or continue here to read more on the incredible solutions and services that we offer.
-
-
Language
-
PRECISION NUTRITION 2022
PharmaBiome AG
PharmaBiome’s disruptive platform combines a context-centered microbiome analysis tool and innovative co-cultivation technology to develop the next generation of targeted microbiome modification therapies. Our bottom-up approach addresses the shortcomings of microbiome translation.
Company Details
Primary Industry: Biotechnology
HQ Location: Zurich, Switzerland
Founded: 2015
Employees: 13
Manufacturing: Lab scale in house
Key Personnel
Dr. Tomas de Wouters
CEO
Dr. Gabriel Leventhal
CSO
Prof. Christophe Lacroix
Founder
Prof. Gerhard Rogler
Founder
Financials & Funding
Maturity: Preclinical-stage drug development
Funding: CHF 10 M total investments dilutive and non-dilutive
Company Introduction
Vision: We decipher microbiome complexity to make the microbiome an integral part of human health management.
Our proprietary microbiome analysis tool - NicheMapTM links microbiome composition to microbiome activity.
The NicheMapTM is a well curated and quantitative reference database with an unprecedented predictive power for the response of complex microbiomes to specific nutrients and the stratification of the response within a population.
Product Portfolio & Key Technologies
The NicheMapTM combines biology-based insights with big data, allowing:
- biomarker discovery
- supplement design and development
- prediction of microbiome response to nutritional interventions
The COMIT platform combines the NicheMapTM with our consortium assembly and co-cultivation technologies to develop first-in-class microbiome therapeutics with highly controlled microbiome modification activities.
M&A, Partnerships or Customers
PharmaBiome developed a fully integrated microbiome development platform and seeks for strategic collaboration in the fields of: microbiome production technologies, design of prebiotics, prediction and personalization of nutrition.
Link to Precision Nutrition
We developed and validated the NicheMapTM in strategic collaborations showing its predictive power for validation and/or development of prebiotic fibers.
The NicheMapTM has shown a huge potential by solving the problem of personalized response prediction for prebiotics.
Our Request
We are looking for strategic partners to leverage our development platform beyond microbiome therapy development in fields like: personalized nutrition, animal health, production of multi-strain probiotics.
We are looking for strategic investors to develop the COMIT platform towards clinical proof of concept.
Contact
Wagistrasse 27, 8952 Schlieren, Switzerland
Dr. Tomas de Wouters, CEO
LinkedIn | t.dewouters@pharmabiome.com